ReviewJournal of orthopaedic translation2026
From microtissues to macro solutions - The future of scalable and automated cartilage tissue engineering.
Review in Journal of orthopaedic translation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging mechanisms and translational advances in musculoskeletal diseases.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of articular cartilage damage on society continues to rise. Suitable treatment is necessary to reduce pain, improve quality of life, and avoid progression into osteoarthritis. Current regenerative cartilage repair strategies remain limited in clinical practice due to high costs, complex logistics, patient burden, and poor reimbursement. To ensure that treatment innovations effectively reach the patient, the focus during development should be on automated and scalable solutions. A promising concept is using cartilage microtissues as building blocks in a modular approach to create larger cartilage constructs. By enabling controlled microtissue assembly and reproducible, scalable manufacturing, this could lead to the efficient production of tissue-engineered cartilage implants. Several automated, scalable steps have been described in literature, ranging from cell isolation and expansion to microtissue formation and harvesting, and finally to macrotissue assembly and maturation. However, integrating all these steps into a single, cost-effective, and automated process remains a conceptual idea. This review focuses on potential routes and key choices that should be considered in the early design process of future ready-to-implant tissue-engineered cartilage implants. Furthermore, the added value of investigating and implementing automatic quality measures and cleaning protocols, as well as the recommended regulatory checks and cost-effectiveness implications, are discussed. The translational potential of this article: Leveraging microtissues for cartilage tissue engineering in a scalable, automated, and GMP-compliant manner could address the growing burden of articular cartilage damage. This review shows the translational potential of this approach by focusing on the early implementation of these concepts in the design process of cartilage tissue-engineered solutions, ensuring compatibility and viability within current healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.